Ország: Egyesült Államok
Nyelv: angol
Forrás: NLM (National Library of Medicine)
FENTANYL (UNII: UF599785JZ) (FENTANYL - UNII:UF599785JZ)
Physicians Total Care, Inc.
FENTANYL
FENTANYL 1.28 mg in 1 [USP'U]
TRANSDERMAL
PRESCRIPTION DRUG
Fentanyl transdermal system is indicated for management of persistent , moderate to severe chronic pain that: - requires continuous, around-the-clock opioid administration for an extended period of time, and - cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids Fentanyl transdermal system should ONLY be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to fentanyl transdermal system 25 mcg/hr (see DOSAGE AND ADMINISTRATION). Patients who are considered opioid-tolerant are those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. Because serious or life-threatening hypoventilation could result, fentanyl transdermal system is contraindicated for use on an as needed basis (i.e., prn
Fentanyl transdermal system is supplied in cartons containing individually packaged systems. Fentanyl Transdermal 12 mcg/hr Fentanyl Transdermal 25 mcg/hr Fentanyl Transdermal 50 mcg/hr Fentanyl Transdermal 75 mcg/hr Fentanyl Transdermal 100 mcg/hr Fentanyl transdermal systems are supplied in sealed pouches which pose little risk of exposure to healthcare workers. Do not use a fentanyl transdermal system if the pouch seal is broken or the patch is cut, damaged, or changed in any way. KEEP FENTANYL TRANSDERMAL SYSTEM OUT OF THE REACH OF CHILDREN AND PETS. Store in original unopened pouch. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Apply immediately after removal from individually sealed pouch. Do not use if the pouch seal is broken. For transdermal use only. A schedule CII narcotic. DEA order form required. BIOCLUSIVE® is a registered trademark of Systagenix Wound Management, Inc. Askina® Derm is a registered trademark of BBraun Melsungen AG DILAUDID® is a registered trademark of Purdue Pharmaceutical Products L.P. DOLOPHINE® is a registered trademark of Roxane Laboratories, Inc. LEVO-DROMORAN® is a registered trademark of Valeant Pharmaceuticals NUMORPHAN® is a registered trademark of Endo Pharmaceuticals, Inc. DEMEROL® is a registered trademark of Sanofi-Synthelabo Inc. of Sanofi-Aventis U.S. Mylan Pharmaceuticals Inc. Morgantown, WV 26505 REVISED DECEMBER 2009 FTS:R17 Relabeling of "Additional" barcode label by: Physicians Total Care, Inc. Tulsa, OK 74146
Abbreviated New Drug Application
FENTANYL - FENTANYL PATCH Physicians Total Care, Inc. ---------- MEDICATION GUIDE FENTANYL TRANSDERMAL SYSTEM IMPORTANT: • Keep fentanyl transdermal system in a safe place away from children and pets. Accidental use by a child or pet is a medical emergency and may result in death. If a child or pet accidentally uses fentanyl transdermal system, get emergency help right away. • Make sure you read the separate “Instructions for Applying a Fentanyl Transdermal System.” Always use a fentanyl transdermal system the right way. Fentanyl transdermal system can cause serious breathing problems and death, especially if it is used the wrong way. • Fentanyl transdermal system is a federally controlled substance (C-II) because it can be abused. Keep fentanyl transdermal system in a safe place to prevent theft. Selling or giving away fentanyl transdermal system may harm others, and is against the law. • Tell your doctor if you (or a family member) have ever abused or been dependent on alcohol, prescription medicines or street drugs. Read the Medication Guide that comes with fentanyl transdermal system before you start using it and each time you get a new prescription. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or your treatment. Make sure you read and understand all the instructions for using fentanyl transdermal system. Do not use fentanyl transdermal system unless you understand everything. Talk to your healthcare provider if you have questions. What is the most important information I should know about fentanyl transdermal system? Fentanyl transdermal system is a skin patch that contains fentanyl. Fentanyl is a very strong opioid narcotic pain medicine that can cause serious and life-threatening breathing problems. Serious and life- threatening breathing problems can happen because of an overdose or if the dose you are using is too high for you. Call your doctor right away or get emergency medical help if you: Olvassa el a teljes dokumentumot
FENTANYL - FENTANYL PATCH PHYSICIANS TOTAL CARE, INC. ---------- FULL PRESCRIBING INFORMATION FOR USE IN OPIOID-TOLERANT PATIENTS ONLY FENTANYL TRANSDERMAL SYSTEM CONTAINS A HIGH CONCENTRATION OF A POTENT SCHEDULE II OPIOID AGONIST, FENTANYL. SCHEDULE II OPIOID SUBSTANCES WHICH INCLUDE FENTANYL, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, AND OXYMORPHONE HAVE THE HIGHEST POTENTIAL FOR ABUSE AND ASSOCIATED RISK OF FATAL OVERDOSE DUE TO RESPIRATORY DEPRESSION. FENTANYL CAN BE ABUSED AND IS SUBJECT TO CRIMINAL DIVERSION. THE HIGH CONTENT OF FENTANYL IN THE PATCHES (FENTANYL TRANSDERMAL SYSTEM) MAY BE A PARTICULAR TARGET FOR ABUSE AND DIVERSION. FENTANYL TRANSDERMAL SYSTEM IS INDICATED FOR MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE CHRONIC PAIN THAT: REQUIRES CONTINUOUS, AROUND-THE-CLOCK OPIOID ADMINISTRATION FOR AN EXTENDED PERIOD OF TIME, AND CANNOT BE MANAGED BY OTHER MEANS SUCH AS NON-STEROIDAL ANALGESICS, OPIOID COMBINATION PRODUCTS, OR IMMEDIATE-RELEASE OPIOIDS FENTANYL TRANSDERMAL SYSTEM SHOULD ONLY BE USED IN PATIENTS WHO ARE ALREADY RECEIVING OPIOID THERAPY, WHO HAVE DEMONSTRATED OPIOID TOLERANCE, AND WHO REQUIRE A TOTAL DAILY DOSE AT LEAST EQUIVALENT TO FENTANYL TRANSDERMAL SYSTEM 25 MCG/HR. PATIENTS WHO ARE CONSIDERED OPIOID-TOLERANT ARE THOSE WHO HAVE BEEN TAKING, FOR A WEEK OR LONGER, AT LEAST 60 MG OF MORPHINE DAILY, OR AT LEAST 30 MG OF ORAL OXYCODONE DAILY, OR AT LEAST 8 MG OF ORAL HYDROMORPHONE DAILY OR AN EQUIANALGESIC DOSE OF ANOTHER OPIOID. BECAUSE SERIOUS OR LIFE-THREATENING HYPOVENTILATION COULD OCCUR, FENTANYL TRANSDERMAL SYSTEM IS CONTRAINDICATED: IN PATIENTS WHO ARE NOT OPIOID-TOLERANT IN THE MANAGEMENT OF ACUTE PAIN OR IN PATIENTS WHO REQUIRE OPIOID ANALGESIA FOR A SHORT PERIOD OF TIME IN THE MANAGEMENT OF POSTOPERATIVE PAIN, INCLUDING USE AFTER OUT-PATIENT OR DAY SURGERIES (E.G., TONSILLECTOMIES) IN THE MANAGEMENT OF MILD PAIN IN THE MANAGEMENT OF INTERMITTENT PAIN [E.G., USE ON AN AS NEEDED BASIS (PRN)] (SEE CONTRAINDICATIONS FOR FURTHER INFORMATION.) SINCE THE PEAK FENTANYL CONCENTRA Olvassa el a teljes dokumentumot